Your fact-checks will appear here
Available reporting about “Lipoless” is sparse and mixed: the brand’s own FAQ highlights gastrointestinal complaints, risk of hypoglycemia with alcohol use, and weight regain after stopping treatment ...
Most recent federal guidance and court rulings say routine compounding of tirzepatide by U.S. compounding pharmacies is no longer protected by FDA enforcement discretion: 503A pharmacies’ grace period...
FDA-approved ivermectin is an antiparasitic available as oral tablets (e.g., Stromectol) for infections such as strongyloidiasis and onchocerciasis, and as topical formulations for conditions like ros...
Available public materials about GaraHerb products list traditional herbal ingredients such as horny goat weed (icariin), saw palmetto, Tribulus terrestris and Chinese hawthorn in their references and...
Report suspected adverse reactions or counterfeit medicines in the U.S. chiefly through the FDA’s MedWatch program (online form, fax 1-800-FDA-0178 or phone 1-800-332-1088); the FDA explicitly tells p...
Available reporting shows no FDA warning letters, public investigations, or enforcement actions specifically naming the supplement “Burn Peak” in the documents and press releases found. Company statem...
Verifying a celebrity‑branded medical product launch requires two parallel proof tracks: hard regulatory and technical evidence that the product itself is lawful, safe and effective, and transparent m...
Severe allergic reactions to products marketed as "Lipoless" are described as rare but potentially life‑threatening, and they require immediate emergency care when they involve facial or throat swelli...
Available sources reviewed do not mention any postmarket adverse reactions specific to a product named "Lipoless"; the supplied documents describe how postmarketing surveillance systems work and what ...
There are no postmarketing surveillance reports for a drug named “neurogold” in the provided sources; available sources describe how postmarketing surveillance works, not specific adverse events for t...